The Impact of Time Horizons on QALY Calculations in Healthcare
By Melike Belenli Gümüş
June 10, 2024
Introduction
Quality-adjusted life years (QALYs) play a pivotal role in determining the cost-effectiveness of treatments, particularly within the National Health Service (NHS) of England and Wales. While theoretically equal, the practical application of QALYs has raised concerns, especially regarding rare diseases and unique patient populations. This article explores the impact of time horizons on QALY calculations and implicitly funding decisions for healthcare treatments.
Understanding QALYs and NICE’s Evaluation
QALYs blend clinical benefit and treatment duration, with the National Institute for Health and Care Excellence (NICE) using them to assess cost-effectiveness. Treatments exceeding GBP 30,000 per QALY gained face funding challenges. However, the application of QALYs across diverse patient groups has sparked debates on fairness and transparency in decision-making processes.
Case Studies: Afamelanotide and Givosiran
Examining evaluations of afamelanotide for erythropoietic protoporphyria and givosiran for acute hepatic porphyria reveals discrepancies in time horizons. The length of time considered for treatment impacts QALY gains and subsequent funding recommendations, highlighting the need for consistency and realism in assessments.
Analysis of Time Horizons in HST Programme
A comprehensive review of time horizons in Highly Specialised Technologies (HST) evaluations uncovers a trend towards extended durations, sometimes surpassing expected treatment periods or life expectancies. Extended time horizons can alter perceived treatment benefits and impact funding decisions, potentially influencing resource allocation within the healthcare system.
Implications and Recommendations
The study underscores the importance of aligning time horizons with clinical realities to ensure equitable funding decisions. Transparent reporting and methodological consistency in QALY calculations are crucial for promoting fairness and trust in healthcare funding processes. Addressing discrepancies and rationalising parameters like time horizons can enhance the integrity of decision-making frameworks.
Conclusion
The analysis calls for a re-evaluation of time horizons in QALY calculations to uphold fairness and accuracy in healthcare funding assessments. By fostering transparency, consistency, and evidence-based decision-making, organisations like NICE can better serve diverse patient populations and uphold the principles of equitable healthcare access.
📊 The burden of hearing loss in Africa is rising, with projections estimating that 54 million people will be affected by 2030 if no action is taken. This alarming increase highlights the urgent need for policy advocacy and improved access to ear and hearing care services.
Discover the key findings from the WHO report and the steps needed to address this pressing issue.
📊 Turkey’s pharmaceutical sector is on the rise! The latest “August 2024 Foreign Trade Analysis” offers a deep dive into the performance and dynamics of foreign trade, showcasing a 3.5% increase in total exports. 🌍 Discover the insights and market trends shaping the future of the pharmaceutical industry in Türkiye.
🌍 Celebrating a decade of **ethical collaboration** among healthcare leaders! Health Policy Watch explores the groundbreaking achievements and future directions of this international consensus. By uniting efforts, we can tackle complex health challenges more effectively.
Read more about the role of ethical collaboration in shaping global health outcomes!
#SyenzaNews #GlobalHealth #EthicalCollaboration
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.